Display options
Cite
Hayashi K, Tabata S, Piras V, et al. Systems Biology Strategy Reveals PKCδ is Key for Sensitizing TRAIL-Resistant Human Fibrosarcoma. Front Immunol. 2015;5:659doi: 10.3389/fimmu.2014.00659.
Hayashi, K., Tabata, S., Piras, V., Tomita, M., & Selvarajoo, K. (2014). Systems Biology Strategy Reveals PKCδ is Key for Sensitizing TRAIL-Resistant Human Fibrosarcoma. Frontiers in immunology, 5659. https://doi.org/10.3389/fimmu.2014.00659
Hayashi, Kentaro, et al. "Systems Biology Strategy Reveals PKCδ is Key for Sensitizing TRAIL-Resistant Human Fibrosarcoma." Frontiers in immunology vol. 5 (2014): 659. doi: https://doi.org/10.3389/fimmu.2014.00659
Hayashi K, Tabata S, Piras V, Tomita M, Selvarajoo K. Systems Biology Strategy Reveals PKCδ is Key for Sensitizing TRAIL-Resistant Human Fibrosarcoma. Front Immunol. 2015 Jan 05;5:659. doi: 10.3389/fimmu.2014.00659. eCollection 2014. PMID: 25601862; PMCID: PMC4283611.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2015 Jan 05;5:659. doi: 10.3389/fimmu.2014.00659. eCollection 2014.

Systems Biology Strategy Reveals PKCδ is Key for Sensitizing TRAIL-Resistant Human Fibrosarcoma.

Frontiers in immunology

Kentaro Hayashi, Sho Tabata, Vincent Piras, Masaru Tomita, Kumar Selvarajoo

Affiliations

  1. Institute for Advanced Biosciences, Keio University , Tsuruoka , Japan ; Systems Biology Program, Graduate School of Media and Governance, Keio University , Fujisawa , Japan.

PMID: 25601862 PMCID: PMC4283611 DOI: 10.3389/fimmu.2014.00659

Abstract

Cancer cells are highly variable and largely resistant to therapeutic intervention. Recently, the use of the tumor necrosis factor related apoptosis-inducing ligand (TRAIL) induced treatment is gaining momentum due to TRAIL's ability to specifically target cancers with limited effect on normal cells. Nevertheless, several malignant cancer types still remain non-sensitive to TRAIL. Previously, we developed a dynamic computational model, based on perturbation-response differential equations approach, and predicted protein kinase C (PKC) as the most effective target, with over 95% capacity to kill human fibrosarcoma (HT1080) in TRAIL stimulation (1). Here, to validate the model prediction, which has significant implications for cancer treatment, we conducted experiments on two TRAIL-resistant cancer cell lines (HT1080 and HT29). Using PKC inhibitor bisindolylmaleimide I, we demonstrated that cell viability is significantly impaired with over 95% death of both cancer types, in consistency with our previous model. Next, we measured caspase-3, Poly (ADP-ribose) polymerase (PARP), p38, and JNK activations in HT1080, and confirmed cell death occurs through apoptosis with significant increment in caspase-3 and PARP activations. Finally, to identify a crucial PKC isoform, from 10 known members, we analyzed each isoform mRNA expressions in HT1080 cells and shortlisted the highest 4 for further siRNA knock-down (KD) experiments. From these KDs, PKCδ produced the most cancer cell death in conjunction with TRAIL. Overall, our approach combining model predictions with experimental validation holds promise for systems biology based cancer therapy.

Keywords: TRAIL; apoptosis; cancer; cell dynamics; computational model; protein kinase C; signaling pathway

References

  1. Oncogene. 2008 Jun 26;27(28):3957-66 - PubMed
  2. Mol Syst Biol. 2007;3:144 - PubMed
  3. Science. 2013 Feb 8;339(6120):646 - PubMed
  4. J Neurooncol. 2012 Sep;109(3):503-12 - PubMed
  5. Cancer Metastasis Rev. 2006 Sep;25(3):409-16 - PubMed
  6. Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):E2875-84 - PubMed
  7. Oncogene. 2003 Jun 19;22(25):3842-52 - PubMed
  8. FEBS Lett. 2006 Feb 20;580(5):1457-64 - PubMed
  9. Biochem Soc Trans. 2004 Aug;32(Pt 4):606-10 - PubMed
  10. Cancer Res. 1999 Feb 1;59(3):734-41 - PubMed
  11. Cell. 2010 Mar 19;140(6):883-99 - PubMed
  12. Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):652-6 - PubMed
  13. J Biol Chem. 1996 May 31;271(22):12687-90 - PubMed
  14. Oncogene. 2003 Nov 24;22(53):8628-33 - PubMed
  15. Cell Death Differ. 2005 Jun;12(6):585-91 - PubMed
  16. Sci Rep. 2014 Nov 20;4:7137 - PubMed
  17. J Biol Chem. 2003 Nov 7;278(45):44338-47 - PubMed
  18. FEBS Lett. 1989 Dec 18;259(1):61-3 - PubMed
  19. Trends Immunol. 2002 Nov;23(11):549-55 - PubMed
  20. Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):5816-21 - PubMed
  21. Biochem J. 1993 Sep 1;294 ( Pt 2):335-7 - PubMed
  22. Mol Cancer Ther. 2006 Sep;5(9):2251-60 - PubMed
  23. PLoS One. 2008;3(10):e3430 - PubMed
  24. Oncogene. 2006 Nov 30;25(56):7434-9 - PubMed
  25. Cancer Res. 2001 Feb 15;61(4):1314-9 - PubMed
  26. Immunol Rev. 2013 May;253(1):237-52 - PubMed
  27. FASEB J. 2002 Dec;16(14):2003-5 - PubMed
  28. J Biol Chem. 1991 Aug 25;266(24):15771-81 - PubMed
  29. Wiley Interdiscip Rev Syst Biol Med. 2012 Jul-Aug;4(4):385-99 - PubMed
  30. Cell Commun Signal. 2011 Apr 20;9:9 - PubMed
  31. PLoS One. 2007 Aug 22;2(8):e776 - PubMed
  32. J Biol Eng. 2014 Aug 19;8:23 - PubMed
  33. Cancer Res. 2001 Feb 1;61(3):1162-70 - PubMed
  34. Immunity. 2003 Jan;18(1):1-6 - PubMed
  35. Clin Cancer Res. 2000 Feb;6(2):335-46 - PubMed
  36. Sci Rep. 2011;1:144 - PubMed
  37. Immunity. 1995 Dec;3(6):673-82 - PubMed
  38. J Bioinform Comput Biol. 2009 Feb;7(1):243-68 - PubMed
  39. Science. 2002 Nov 8;298(5596):1241-5 - PubMed
  40. Nat Rev Cancer. 2008 Oct;8(10):782-98 - PubMed
  41. Toxicol Pathol. 2007 Jun;35(4):495-516 - PubMed
  42. Cancer Res. 2005 Aug 15;65(16):7301-9 - PubMed
  43. Cell Commun Signal. 2013 Nov 07;11:84 - PubMed
  44. Nat Med. 2000 May;6(5):564-7 - PubMed
  45. PLoS One. 2009;4(3):e4661 - PubMed
  46. J Biol Chem. 2005 Dec 9;280(49):40599-608 - PubMed
  47. Mol Cell. 2006 Aug 4;23(3):401-12 - PubMed
  48. FEBS Lett. 2000 Oct 6;482(3):193-9 - PubMed

Publication Types